A combination of the protease inhibitor BI 201335 (120 mg per day), the polymerase inhibitor BI 207127 (400 mg or 600 mg three times a day) and ribavirin (1,000–1,200 mg per day) for 4 weeks was safe and efficacious in 32 treatment-naive patients chronically infected with HCV genotype 1. In the group given 600 mg of BI 207127, the virological response was 100% by day 29, compared with 73% in those given 400 mg. The response to this combination was rapid and strong, and none of the patients experienced a severe adverse event.
ORIGINAL RESEARCH PAPER
Zeuzem, S. et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology doi: 10.1053/j.gastro.2011.08.051
Rights and permissions
About this article
Cite this article
New therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 8, 601 (2011). https://doi.org/10.1038/nrgastro.2011.187
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.187